Qinlock (ripretinib) is indicated to treat adult patients with advanced gastrointestinal stromal tumors (GIST).
The drug from Qinlock won FDA approval on May 15, 2020.
In the Phase 3 INVICTUS study, the drug demonstrated clinical benefits with dose escalation for patients with advanced gastrointestinal stromal tumors with disease progression.
Filed Under: Oncology
Tell Us What You Think!
You must be logged in to post a comment.